These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32572045)

  • 1. Adeno-associated virus-binding antibodies detected in cats living in the Northeastern United States lack neutralizing activity.
    Adachi K; Dissen GA; Lomniczi A; Xie Q; Ojeda SR; Nakai H
    Sci Rep; 2020 Jun; 10(1):10073. PubMed ID: 32572045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-existing antibodies to candidate gene therapy vectors (adeno-associated vector serotypes) in domestic cats.
    Li P; Boenzli E; Hofmann-Lehmann R; Helfer-Hungerbuehler AK
    PLoS One; 2019; 14(3):e0212811. PubMed ID: 30897117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of Pre-Existing Neutralizing Antibodies Against Adeno-Associated Virus Serotypes 1, 2, 5, 6, 8, and 9 in Sera of Different Pig Strains.
    Dai Y; Kavita U; Lampen MH; Gielen S; Banks G; Levesque P; Kozhich A; Pillutla R; Zhang Y; Jawa V; Adam L
    Hum Gene Ther; 2022 Apr; 33(7-8):451-459. PubMed ID: 34913759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models.
    Rapti K; Louis-Jeune V; Kohlbrenner E; Ishikawa K; Ladage D; Zolotukhin S; Hajjar RJ; Weber T
    Mol Ther; 2012 Jan; 20(1):73-83. PubMed ID: 21915102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of Neutralizing Antibodies against Adeno-Associated Virus Serotypes 1, 2, and 9 in Non-Injected Latin American Patients with Heart Failure-ANVIAS Study.
    Sierra-Delgado JA; Likhite S; Bautista PK; Gómez-Ochoa SA; Echeverría LE; Guío E; Vargas C; Serrano NC; Meyer KC; Rincon MY
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2.
    Rutledge EA; Halbert CL; Russell DW
    J Virol; 1998 Jan; 72(1):309-19. PubMed ID: 9420229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in Duchenne Muscular Dystrophy patients.
    Leborgne C; Latournerie V; Boutin S; Desgue D; Quéré A; Pignot E; Collaud F; Charles S; Simon Sola M; Masat E; Jouen F; Boyer O; Masurier C; Mingozzi F; Veron P
    Cell Immunol; 2019 Aug; 342():103780. PubMed ID: 29571923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease.
    Janelidze S; Nordström U; Kügler S; Brundin P
    J Gene Med; 2014; 16(9-10):300-8. PubMed ID: 25303717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A.
    Klamroth R; Hayes G; Andreeva T; Gregg K; Suzuki T; Mitha IH; Hardesty B; Shima M; Pollock T; Slev P; Oldenburg J; Ozelo MC; Stieltjes N; Castet SM; Mahlangu J; Peyvandi F; Kazmi R; Schved JF; Leavitt AD; Callaghan M; Pan-Petesch B; Quon DV; Andrews J; Trinh A; Li M; Wong WY
    Hum Gene Ther; 2022 Apr; 33(7-8):432-441. PubMed ID: 35156839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of polyploid adeno-associated virus vectors for transduction enhancement and neutralizing antibody evasion.
    Chai Z; Sun J; Rigsbee KM; Wang M; Samulski RJ; Li C
    J Control Release; 2017 Sep; 262():348-356. PubMed ID: 28789965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adeno-associated virus serotype 1 (AAV1)- and AAV5-antibody complex structures reveal evolutionary commonalities in parvovirus antigenic reactivity.
    Tseng YS; Gurda BL; Chipman P; McKenna R; Afione S; Chiorini JA; Muzyczka N; Olson NH; Baker TS; Kleinschmidt J; Agbandje-McKenna M
    J Virol; 2015 Feb; 89(3):1794-808. PubMed ID: 25410874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of naturally-occurring humoral immunity to AAV in sheep.
    Tellez J; Van Vliet K; Tseng YS; Finn JD; Tschernia N; Almeida-Porada G; Arruda VR; Agbandje-McKenna M; Porada CD
    PLoS One; 2013; 8(9):e75142. PubMed ID: 24086458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy.
    Louis Jeune V; Joergensen JA; Hajjar RJ; Weber T
    Hum Gene Ther Methods; 2013 Apr; 24(2):59-67. PubMed ID: 23442094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles.
    Li C; Diprimio N; Bowles DE; Hirsch ML; Monahan PE; Asokan A; Rabinowitz J; Agbandje-McKenna M; Samulski RJ
    J Virol; 2012 Aug; 86(15):7752-9. PubMed ID: 22593151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler-Najjar Syndrome.
    Aronson SJ; Veron P; Collaud F; Hubert A; Delahais V; Honnet G; de Knegt RJ; Junge N; Baumann U; Di Giorgio A; D'Antiga L; Ginocchio VM; Brunetti-Pierri N; Labrune P; Beuers U; Bosma PJ; Mingozzi F
    Hum Gene Ther; 2019 Oct; 30(10):1297-1305. PubMed ID: 31502485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue.
    Mingozzi F; Chen Y; Edmonson SC; Zhou S; Thurlings RM; Tak PP; High KA; Vervoordeldonk MJ
    Gene Ther; 2013 Apr; 20(4):417-24. PubMed ID: 22786533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prevalence of neutralizing antibodies against adeno-associated virus capsids is reduced in young Japanese individuals.
    Mimuro J; Mizukami H; Shima M; Matsushita T; Taki M; Muto S; Higasa S; Sakai M; Ohmori T; Madoiwa S; Ozawa K; Sakata Y
    J Med Virol; 2014 Nov; 86(11):1990-7. PubMed ID: 24136735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping an Adeno-associated Virus 9-Specific Neutralizing Epitope To Develop Next-Generation Gene Delivery Vectors.
    Giles AR; Govindasamy L; Somanathan S; Wilson JM
    J Virol; 2018 Oct; 92(20):. PubMed ID: 30089698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
    Sun J; Hua B; Chen X; Samulski RJ; Li C
    Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors.
    Halbert CL; Miller AD; McNamara S; Emerson J; Gibson RL; Ramsey B; Aitken ML
    Hum Gene Ther; 2006 Apr; 17(4):440-7. PubMed ID: 16610931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.